Lupus drug combo tested in tiny trial – but study halted early

NCT ID NCT05306873

Terminated Disease control Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This phase 2 trial tested the drugs mycophenolate mofetil (CellCept) alone or with voclosporin in 12 people with lupus. The goal was to see if these treatments work better in certain patient groups. However, the study was terminated early, so the results are very limited.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Mycophenolate mofetil (CellCept) and voclosporin
What this could lead to: If successful, this could point toward better ways to match lupus treatments to specific patient types, improving disease control.
What could go wrong: This was a very small, early-phase trial that was terminated early, so results are limited. It is unclear if the drugs will work better than existing options.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SYSTEMIC LUPUS ERYTHEMATOSUS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

systemic lupus erythematosus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SYSTEMIC LUPUS ERYTHEMATOSUS

Contacts and locations

Locations

Columbia University Medical Center: Department of Medicine, Division of Rheumatology

New York, New York, 10032, United States
Emory University School of Medicine: Division of Rheumatology

Atlanta, Georgia, 30307, United States
Feinstein Institute for Medical Research: Center for Autoimmune and Musculoskeletal Diseases

Manhasset, New York, 11030, United States
Massachusetts General Hospital: Rheumatology, Allergy and Immunology, Center for Immunology and Inflammatory Diseases

Boston, Massachusetts, 02114, United States
Oklahoma Medical Research Foundation: Arthritis and Clinical Immunology Research Program

Oklahoma City, Oklahoma, 73104, United States
PennState Health Milton S. Hershey Medical Center: Division of Rheumatology

Hershey, Pennsylvania, 17033, United States
Piedmont Healthcare: Rheumatology Atlanta

Atlanta, Georgia, 30318, United States
UCLA Medical Center: Division of Rheumatology

Los Angeles, California, 90095, United States
University of North Carolina at Chapel Hill; Thurston Arthritis Research Center: Division of Rheumatology, Allergy, and Immunology

Chapel Hill, North Carolina, 27599, United States
Yale University School of Medicine: Rheumatology, Allergy & Immunology

New Haven, Connecticut, 06519, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.